BR112017000022A2 - nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas - Google Patents

nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas

Info

Publication number
BR112017000022A2
BR112017000022A2 BR112017000022A BR112017000022A BR112017000022A2 BR 112017000022 A2 BR112017000022 A2 BR 112017000022A2 BR 112017000022 A BR112017000022 A BR 112017000022A BR 112017000022 A BR112017000022 A BR 112017000022A BR 112017000022 A2 BR112017000022 A2 BR 112017000022A2
Authority
BR
Brazil
Prior art keywords
producing
methods
particles
targeted therapeutic
therapeutic nanoparticles
Prior art date
Application number
BR112017000022A
Other languages
English (en)
Inventor
Wang Hong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112017000022A2 publication Critical patent/BR112017000022A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

a presente invenção refere-se a nanopartículas poliméricas que incluem um agente terapêutico, bem como se refere a métodos de produção e uso dessas nanopartículas terapêuticas. em algumas modalidades da presente invenção, as nanopartículas contempladas podem incluir um excipiente.
BR112017000022A 2014-07-03 2015-07-02 nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas BR112017000022A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462020609P 2014-07-03 2014-07-03
PCT/US2015/038963 WO2016004290A1 (en) 2014-07-03 2015-07-02 Targeted therapeutic nanoparticles and methods of making and using same

Publications (1)

Publication Number Publication Date
BR112017000022A2 true BR112017000022A2 (pt) 2017-11-07

Family

ID=53724455

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000022A BR112017000022A2 (pt) 2014-07-03 2015-07-02 nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas

Country Status (12)

Country Link
US (3) US10182996B2 (pt)
EP (1) EP3164119B1 (pt)
KR (2) KR20170023173A (pt)
CN (1) CN107072962A (pt)
AU (1) AU2015284017A1 (pt)
BR (1) BR112017000022A2 (pt)
CA (1) CA2953996A1 (pt)
ES (1) ES2847894T3 (pt)
IL (1) IL249894A0 (pt)
MX (1) MX2017000141A (pt)
RU (1) RU2706791C2 (pt)
WO (1) WO2016004290A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180115750A (ko) * 2016-03-25 2018-10-23 화이자 인코포레이티드 치료 입자를 동결건조시키기 위한 안정한 제제
WO2018073740A1 (en) * 2016-10-20 2018-04-26 Pfizer Inc. Therapeutic polymeric nanoparticles comprising lipids and methods of making and using same
WO2018141810A1 (en) * 2017-01-31 2018-08-09 Alf Lamprecht Use of nanoparticles for immunotherapy
US10369230B2 (en) 2017-04-06 2019-08-06 National Guard Health Affairs Sustained release of a therapeutic agent from PLA-PEG-PLA nanoparticles for cancer therapy
WO2019057113A1 (en) * 2017-09-22 2019-03-28 Jingjie Ptm Biolab (Hangzhou) Co., Ltd. CAPECITABINE POLYMER-LIPID HYBRID NANOPARTICLES USING MICROMELIN AND AMPHIPHILIC CAPECITABINE PROPERTIES
KR20240035317A (ko) * 2022-09-08 2024-03-15 주식회사 삼양홀딩스 약물 함유 나노입자 제조용 키트 및 약물전달용 나노입자 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002568A2 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US8313777B2 (en) * 2006-10-05 2012-11-20 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
US20090148384A1 (en) * 2007-12-10 2009-06-11 Fischer Katrin Functionalized, solid polymer nanoparticles comprising epothilones
CN102099016A (zh) * 2008-06-16 2011-06-15 佰恩德生物科学股份有限公司 载药的聚合物纳米微粒及其制备和使用方法
JP2012501966A (ja) * 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法
EA020954B1 (ru) * 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
WO2010002576A1 (en) * 2008-07-01 2010-01-07 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
NZ595902A (en) * 2009-04-24 2014-10-31 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
ES2780156T3 (es) * 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
WO2012101242A1 (en) * 2011-01-27 2012-08-02 Capsulution Pharma Ag Novel pharmaceutical suspension for parenteral application
US20130149381A1 (en) * 2011-12-08 2013-06-13 Centro De Investigacion En Quimica Aplicada Absorption method for entrapment of drugs in polymeric nanoparticles
BR112014014262A2 (pt) * 2011-12-14 2017-06-13 Univ Johns Hopkins nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
EP2804632B1 (en) * 2012-01-19 2019-09-18 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
CN103585634A (zh) * 2013-10-22 2014-02-19 汤民 一种多西他赛聚合物纳米药物制剂及其制备方法

Also Published As

Publication number Publication date
US20170128380A1 (en) 2017-05-11
EP3164119A1 (en) 2017-05-10
AU2015284017A1 (en) 2017-01-05
RU2706791C2 (ru) 2019-11-21
WO2016004290A1 (en) 2016-01-07
KR20170023173A (ko) 2017-03-02
IL249894A0 (en) 2017-03-30
RU2016149734A (ru) 2018-08-06
KR20190018052A (ko) 2019-02-20
US20200306201A1 (en) 2020-10-01
EP3164119B1 (en) 2020-11-18
US10182996B2 (en) 2019-01-22
RU2016149734A3 (pt) 2018-08-06
CN107072962A (zh) 2017-08-18
US20190151251A1 (en) 2019-05-23
ES2847894T3 (es) 2021-08-04
MX2017000141A (es) 2017-04-25
CA2953996A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
BR112017000022A2 (pt) nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas
CR20150189A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas
CL2016000354A1 (es) Modulación de la inmunidad tumoral
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
MX2015011753A (es) Metodos para tratar cancer de vegija.
UY34218A (es) MÉTODO DE DETECCIÓN DEL EVENTO DE SOJA pDAB9582.814.19.1
UY36075A (es) Derivados de tubulisina
BR112017023560A2 (pt) composição de polímero reforçada com fibra, e, artigo.
MX2015011056A (es) Entrecruzamiento de tejido ocular.
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
CO2017002472A2 (es) Formulación de acetato de abiraterona
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112015007843A2 (pt) método para a preparação de um polímero, polímero, artigo e método de preparação de um artigo
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
BR112018006870A2 (pt) nanopartículas terapêuticas que compreendem um agente terapêutico e métodos para a produção e o uso das mesmas
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
MX2015013021A (es) 5-bromo-indirrubinas.
BR112017002915A2 (pt) processo para manufaturar um dispositivo de uso médico customizável e dispositivo obtido pelo dito processo
AR097827A1 (es) Fracción de gasoil derivada de un proceso de fischer-tropsch
PH12016500820A1 (en) Sesame oil based injection formulations

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2626 DE 04-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.